-
Review
-
- Current status and perspective on molecular targets and therapeutic intervention strategy in hepatic ischemia-reperfusion injury
-
Jia Liu, Ranyi Luo, Yinhao Zhang, Xiaojiaoyang Li
-
School of Life Sciences, Beijing University of Chinese Medicine, Beijing, 100029, China
- Corresponding author: Xiaojiaoyang Li ,Email: xiaojiaoyang.li@bucm.edu.cn
- Received: April 3, 2024; Revised: June 25, 2024 Accepted: June 26, 2024.
- Abstract
- Hepatic ischemia‒reperfusion injury (HIRI) is a common and inevitable complication of hepatic trauma, liver resection, or liver transplantation. It contributes to postoperative organ failure or tissue rejection, eventually affecting patient prognosis and overall survival. The pathological mechanism of HIRI is highly complex and has not yet been fully elucidated. The proposed underlying mechanisms include mitochondrial damage, oxidative stress imbalance, abnormal cell death, immune cell hyperactivation, intracellular inflammatory disorders and other complex events. In addition to serious clinical limitations, available antagonistic drugs and specific treatment regimens are still lacking. Therefore, there is an urgent need to not only clarify the exact etiology of HIRI but also reveal the possible reactions and bottlenecks of existing drugs, helping to reduce morbidity and shorten hospitalizations. We analyzed the possible underlying mechanism of HIRI, discussed various outcomes among different animal models and explored neglected potential therapeutic strategies for HIRI treatment. By thoroughly reviewing and analyzing the literature on HIRI, we gained a comprehensive understanding of the current research status in related fields and identified valuable references for future clinical and scientific investigations.
Keywords :Hepatic ischemia-reperfusion injury; liver diseases; Animal model; Potential drug development
